-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Olin Biotech (688319.SH) issued an announcement. The company recently received a summary report on the phase III clinical study of recombinant Staphylococcus aureus vaccine (Escherichia coli) (“recombinant Staphylococcus aureus vaccine”). The recombinant Staphylococcus aureus vaccine has significant and stable protective effects in preventing Staphylococcus aureus infection after surgery, can induce a rapid and effective specific immune response, and shows good safety characteristics. Clear and favorable benefits-risk assessment can support its marketing application for “prevention of Staphylococcus aureus infection after orthopedic surgery”.

Zhitongcaijing·10/19/2026 14:33:12
Listen to the news
Zhitong Finance App News, Olin Biotech (688319.SH) issued an announcement. The company recently received a summary report on the phase III clinical study of recombinant Staphylococcus aureus vaccine (Escherichia coli) (“recombinant Staphylococcus aureus vaccine”). The recombinant Staphylococcus aureus vaccine has significant and stable protective effects in preventing Staphylococcus aureus infection after surgery, can induce a rapid and effective specific immune response, and shows good safety characteristics. Clear and favorable benefits-risk assessment can support its marketing application for “prevention of Staphylococcus aureus infection after orthopedic surgery”.